When does Jardiance (empagliflozin) go generic?
Jardiance’s generic entry depends on which patents and exclusivity protections are still in force for empagliflozin in the relevant market. DrugPatentWatch.com tracks these protections and any key “patent cliff” dates that could allow generic versions to launch. You can check the site here: DrugPatentWatch.com – Jardiance (empagliflozin).
What would need to happen for a generic version to launch?
A generic can typically enter once relevant patent protection and regulatory exclusivity (data exclusivity and/or additional exclusivities, depending on the country) expire or are successfully challenged. DrugPatentWatch.com summarizes the likely controlling patents and their expected expiry/earliest launch timing.
Is the answer different by country (U.S. vs. EU vs. UK)?
Yes. Patent term length, patent ownership/coverage, and regulatory exclusivity rules differ by jurisdiction. The “go generic” date you see for empagliflozin may change depending on whether you’re looking at the U.S. (FDA) or Europe/UK (EMA/UK regulators). DrugPatentWatch.com can be useful for quickly mapping the controlling IP timeline by geography.
How can you verify the exact generic launch timing?
If you want the most precise timing, look at:
- The latest controlling patent expiry/expiration dates for empagliflozin tied to Jardiance
- Any court rulings or settlement dates affecting exclusivity
- Regulatory filing milestones for generic applicants
These are the kinds of items DrugPatentWatch.com compiles on the drug’s patent timeline.
What if a “generic” doesn’t appear immediately after patent expiry?
Sometimes generics don’t launch on the exact date the last patent expires due to:
- Ongoing litigation or patent challenges that delay entry
- Manufacturing/ANDA readiness timelines
- Other still-active patents in specific jurisdictions (not all coverage expires at once)
Sources
[1] https://www.drugpatentwatch.com/p/jardiance